Comparison of MEI Pharma Inc. (MEIP) and Incyte Corporation (NASDAQ:INCY)

As Biotechnology companies, MEI Pharma Inc. (NASDAQ:MEIP) and Incyte Corporation (NASDAQ:INCY) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MEI Pharma Inc. 2 36.80 60.19M -0.07 0.00
Incyte Corporation 88 0.64 181.76M 1.86 50.69

Table 1 highlights MEI Pharma Inc. and Incyte Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has MEI Pharma Inc. and Incyte Corporation’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
MEI Pharma Inc. 2,903,941,718.53% -11.3% -6.3%
Incyte Corporation 206,193,987.52% 18.7% 14%

Volatility & Risk

MEI Pharma Inc.’s volatility measures that it’s 65.00% more volatile than Standard and Poor’s 500 due to its 1.65 beta. Incyte Corporation on the other hand, has 0.98 beta which makes it 2.00% less volatile compared to Standard and Poor’s 500.

Liquidity

6.8 and 6.8 are the respective Current Ratio and a Quick Ratio of MEI Pharma Inc. Its rival Incyte Corporation’s Current and Quick Ratios are 5 and 5 respectively. MEI Pharma Inc. has a better chance of clearing its pay short and long-term debts than Incyte Corporation.

Analyst Recommendations

In next table is shown MEI Pharma Inc. and Incyte Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MEI Pharma Inc. 0 0 0 0.00
Incyte Corporation 0 6 6 2.50

Meanwhile, Incyte Corporation’s average price target is $89, while its potential upside is 10.50%.

Institutional & Insider Ownership

MEI Pharma Inc. and Incyte Corporation has shares owned by institutional investors as follows: 59.4% and 96.6%. About 0.5% of MEI Pharma Inc.’s share are owned by insiders. Comparatively, 0.5% are Incyte Corporation’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MEI Pharma Inc. 0% 5.95% 12.64% -22.22% -24.03% -25.76%
Incyte Corporation 0.34% 12.91% 19.64% 23.02% 45.13% 48.58%

For the past year MEI Pharma Inc. has -25.76% weaker performance while Incyte Corporation has 48.58% stronger performance.

Summary

On 8 of the 12 factors Incyte Corporation beats MEI Pharma Inc.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companyÂ’s clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.